SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

Neurocrine’s Crenessity is an oral corticotropin-releasing factor type 1 receptor antagonist. Credit: Piotr Swat/Shutterstock. Neurocrine Biosciences has presented new one-year data from its Phase III ...

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.